In patients with suspected dementia with Lewy bodies, the detection of the disease-
associated α-synuclein in easily accessible tissues amenable to be collected using …

Background Given the difficult clinical differential diagnosis between Alzheimer's disease
(AD) and dementia with Lewy bodies (DLB), growing interest resulted in research on α …

Background Several studies have investigated the value of alpha-synuclein assay in the
cerebrospinal fluid (CSF) of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) …

The detection of α-synuclein (α-syn) in the cerebrospinal fluid (CSF) of patients with
synucleinopathy has yielded promising but inconclusive results. The aim of the present …

With the aim to evaluate the significance and reliability of detecting disease-specific α-
synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We …

Abstract α‐Synuclein is the major component of Lewy bodies and a candidate biomarker for
neurodegenerative diseases in which Lewy bodies are common, including Parkinson's …

Abstract Introduction The ability of Alzheimer's disease (AD) cerebrospinal fluid (CSF)
biomarkers (amyloid β peptide 1–42, total tau, and phosphorylated tau) to discriminate AD …

Dementia with Lewy bodies (DLB) is a common subtype of dementia in the elderly. DLB is
neuropathologically characterized by the presence of Lewy bodies and Lewy neurites, both …

Background Parkinson's disease (PD) is a neurodegenerative disorder whose diagnosis is
often challenging because symptoms may overlap with neurodegenerative parkinsonisms …

Background/Aims: Detection and differentiation of neurodegenerative dementias, such as
dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), with blood-based …